Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Eide

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2008
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinibThomas O'Hare, Christopher A Eide, Jeffrey W Tyner, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard TherapiesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Blood|September 13, 2011
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemiaThomas O'Hare, Matthew S Zabriskie, Christopher A Eide, et al.
Haematologica|July 8, 2021
Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemiaJessica Leonard, Joelle Sj Wolf, Michelle Degnin, et al.
Cold Spring Harbor Molecular Case Studies|October 28, 2022
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemiaMara W Rosenberg, Samantha L Savage, Christopher A Eide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Cancer Research|April 21, 2011
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profileChristopher A Eide, Lauren T Adrian, Jeffrey W Tyner, et al.
Cancer Research|July 27, 2013
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitorsAmie S Corbin, Thomas O'Hare, Zhimin Gu, et al.
Cell Reports|March 30, 2017
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid LeukemiaAlyssa Carey, David K Edwards, Christopher A Eide, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasm cellsBruna Alves Fenerich, Jaqueline Cristina Fernandes, Ana Paula Nunes Rodrigues Alves, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2008
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinibThomas O'Hare, Christopher A Eide, Jeffrey W Tyner, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard TherapiesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Blood|September 13, 2011
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemiaThomas O'Hare, Matthew S Zabriskie, Christopher A Eide, et al.
Haematologica|July 8, 2021
Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemiaJessica Leonard, Joelle Sj Wolf, Michelle Degnin, et al.
Cold Spring Harbor Molecular Case Studies|October 28, 2022
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemiaMara W Rosenberg, Samantha L Savage, Christopher A Eide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Cancer Research|April 21, 2011
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profileChristopher A Eide, Lauren T Adrian, Jeffrey W Tyner, et al.
Cancer Research|July 27, 2013
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitorsAmie S Corbin, Thomas O'Hare, Zhimin Gu, et al.
Cell Reports|March 30, 2017
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid LeukemiaAlyssa Carey, David K Edwards, Christopher A Eide, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasm cellsBruna Alves Fenerich, Jaqueline Cristina Fernandes, Ana Paula Nunes Rodrigues Alves, et al.
Pageof 9